Fmoc-N-Me-Ala-OH

CAS No. 84000-07-7

Fmoc-N-Me-Ala-OH( —— )

Catalog No. M22338 CAS No. 84000-07-7

Fmoc-N-Me-Ala-OH, an N-Fmoc-N-methyl amino acid, is available for the peptide-coupling reaction.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 37 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fmoc-N-Me-Ala-OH
  • Note
    Research use only, not for human use.
  • Brief Description
    Fmoc-N-Me-Ala-OH, an N-Fmoc-N-methyl amino acid, is available for the peptide-coupling reaction.
  • Description
    Fmoc-N-Me-Ala-OH, an N-Fmoc-N-methyl amino acid, is available for the peptide-coupling reaction.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    84000-07-7
  • Formula Weight
    325.36
  • Molecular Formula
    C19H19NO4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (307.35 mM)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Harris KS, et al. Rapid optimization of a peptide inhibitor of malaria parasite invasion by comprehensive N-methyl scanning. J Biol Chem. 2009 Apr 3;284(14):9361-71.
molnova catalog
related products
  • Kakuol

    Kakuol has antifungal activity, it can completely inhibit the mycelial growth of Botrytis cinerea Pers ex Fr and Cladosporium cucumerinum Ellis & Arthur at 5 microg ml(-1) and 3 microg ml(-1), respectively.

  • Ac-MBP 1-11

    Ac-MBP 1-11, a short peptide sequence, is the major encephalitogenic epitope in myelin basic protein (MBP).

  • Dehydrojuncusol

    Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.